Kodiak Sciences Inc Common Stock (KOD)

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical stu…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

141

Website

kodiak.com/

Fundamentals

1-day range

$37.4$39.62

Market cap

$2.49B

P/E (trailing)

—

P/E (forward)

-10.07

EPS (trailing)

$-4.17

Dividend yield

—

Beta

2.21

Avg. volume

704.0K

Forecasts

5 analyst ratings

Kodiak Sciences Inc Common Stock Competitors

Chosen by industry and closest market cap.

• KOD

  Kodiak Sciences Inc Common Stock

  $37.77

  ▼ 3.45%
  Market cap $2.49BP/E —
  $8.29$47.84
• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.67BP/E —
  $16.02$38.26
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.10BP/E —
  $23$55.42
• MESO

  Mesoblast Limited American Depositary Shares

  $17.42

  ▼ 4.18%
  Market cap $1.87BP/E —
  $1.88$3.31
• RXRX

  Recursion Pharmaceuticals Inc. Class A Common Stock

  $3.33

  ▼ 3.20%
  Market cap $1.69BP/E —
  $2.77$7.18
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.60BP/E —
  $3.5$21.27
• GLUE

  Monte Rosa Therapeutics Inc. Common Stock

  $13.37

  ▼ 6.63%
  Market cap $1.30BP/E —
  $4.6$25.77

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 10 Health Care Stocks Whale Activity In Today’s Session
  Benzinga · 8/25/2026
• HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
  benzinga · 8/17/2026
• HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
  Benzinga · 8/17/2026
• Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate
  Benzinga · 8/13/2026
• Kodiak Sciences Enrols First Patients In Global Phase 3 ALTO Trial Evaluating KSI-501 In Patients With Diabetic Macular Edema
  Benzinga · 8/10/2026
• JP Morgan Maintains Overweight on Kodiak Sciences, Raises Price Target to $66
  Benzinga · 8/3/2026

• Victor Perlroth · July 15, 2026 · Grant

  100.0K
• John A. Borgeson · July 15, 2026 · Grant

  66.5K
• Bassil I. Dahiyat · June 30, 2026 · Grant

  17.7K
• Bancroft Charles A · June 30, 2026 · Grant

  17.7K
• Richard S. Levy · June 30, 2026 · Grant

  17.7K
• Yang Taiyin · June 30, 2026 · Grant

  17.7K
• Robert Profusek · June 30, 2026 · Grant

  17.7K
• BAKER BROS. ADVISORS LP · June 30, 2026 · Grant

  17.7K
• John A. Borgeson · June 4, 2026 · Option Exercise

  30.0K @ $1.04
• John A. Borgeson · June 4, 2026 · Sale

  4.1K @ $34.67
• John A. Borgeson · June 4, 2026 · Sale

  25.9K @ $34.01
• John A. Borgeson · April 15, 2026 · Option Exercise

  28.6K @ $1.04
• John A. Borgeson · April 2, 2026 · Option Exercise

  30.0K @ $1.04
• John A. Borgeson · April 2, 2026 · Sale

  600 @ $41.77
• John A. Borgeson · April 2, 2026 · Sale

  4.2K @ $40.88

Institutional Ownership

March 31, 2026

Total shares held

58.17M

Total value held

$2.10B

Institutional holders

185